Songtao Shi

This inventor holds 15 USPTO granted patents and 10 published patent applications, plus 6 CIPO patents and 11 EPO patents. Top assignees: University of Southern California, The United States of America, as Represented by the Secretary, Department of Health and Human Services, Angioblast Systems, Inc.. Active years: 2006-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Songtao Shi. Retrieved from https://idiyas.com/inventor/songtao-shi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 10)

% Patents Active = 80.0

CIPO Patents = 6

EPO Patents = 11 (Patent Applications = 5)

Average Co-Inventor Count = 3.1

ph-index = 3

Forward Citations = 88(Granted Patents)

Location History:

Gaithersburg, MD (US) (2006)
Irvine, CA (US) (2010 - 2018)
North Potomac, MD (US) (2011 - 2019)
Los Angeles, CA (US) (2017 - 2019)
Thousand Oaks, CA (US) (2018 - 2021)

Company Filing History:

7 out of 1,695

University of Southern California

patents

6 out of 3,697

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

1 out of 9

Angioblast Systems, Inc.

University System of Maryland

patents

where one patent can have more than one assignee

Years Active: 2006-2021

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10889804 - Pancreatic stromal progenitor cells (2021-01-12),

2. 10736922 - High telomerase activity bone marrow mesenchymal stem cells, methods of producing the same and pharmaceuticals and treatment methods based thereon (2020-08-11),

3. 10646518 - Apoptotic bodies (2020-05-12),

4. 10421946 - Perivascular mesenchymal precursor cells (2019-09-24),

5. 10232080 - Mesenchymal stem cell-mediated function tooth regeneration (2019-03-19),

6. 10098913 - Composition of stem cells having highly expressed FAS ligand (2018-10-16),

7. 10098333 - Method for treating an SLE-like autoimmune disease in a human subject consisting of administering stem cells from human exfoliated deciduous teeth (SHED) and erythropoietin (EPO) to said human subject (2018-10-16),

8. 10046012 - Multipotent postnatal stem cells from human periodontal ligament and uses thereof (2018-08-14),

9. 9682107 - Postnatal stem cells and uses thereof (2017-06-20),

10. 9210925 - Multipotent postnatal stem cells from human periodontal ligament and uses thereof (2015-12-15),

11. 9175264 - Postnatal stem cells and uses thereof (2015-11-03),

12. 8545888 - Tendon stem cells (2013-10-01),

13. 7947266 - Perivascular mesenchymal precursor cells (2011-05-24),

14. 7732126 - Integrin CD18 is a novel stromal stem cell marker and functions to promote osteogenesis (2010-06-08),

15. 7052907 - Adult human dental pulp stem cells in vitro and in vivo (2006-05-30),

Title: Innovator Spotlight: Songtao Shi

Introduction

Songtao Shi, an accomplished inventor based in Irvine, CA, holds an impressive portfolio of 15 patents. His innovative contributions significantly advance the fields of stem cell research and diabetes treatment. Songtao's dedication to scientific exploration and innovative solutions has positioned him as a prominent figure in biotechnology.

Latest Patents

Among Shi’s latest patents is a groundbreaking disclosure regarding pancreatic stromal progenitor cells. This invention covers the isolation of these cells and the composition involving them. Furthermore, it outlines treatment methodologies for diabetes mellitus, showcasing the potential of pancreatic stromal progenitor cells in revolutionizing diabetes therapies.

Another notable patent involves high telomerase activity in bone marrow mesenchymal stem cells, which also includes methods for producing such cells and pharmaceuticals based on these innovations. This patent provides a foundation for further advancements in regenerative medicine by leveraging the unique properties of these specialized stem cells.

Career Highlights

Songtao Shi has had a remarkable career, primarily associated with distinguished institutions such as the University of Southern California and the United States Department of Health and Human Services. His work in these organizations has been pivotal in advancing medical research and developing innovative therapies.

Collaborations

Throughout his career, Songtao has collaborated with notable professionals in the field, including Stan Gronthos and Masako Miura. These collaborations have enhanced the scope of his research and facilitated significant advancements in stem cell applications and therapies.

Conclusion

In conclusion, Songtao Shi exemplifies the spirit of innovation in the realm of biotechnology and stem cell research. His extensive patent portfolio and collaborative efforts contribute to meaningful progress in treating diseases such as diabetes. As he continues to push the boundaries of science, his work inspires future generations of inventors and researchers.

Profile summary based on public USPTO records.